Sign in

CIK 0001919246 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Pelthos Therapeutics Inc.

Sign in to watch
Ticker
PTHS
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
NV
Entity type
operating
EIN
863335449
Phone
919-908-2422
Business address
4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
Former names
Channel Therapeutics Corp, Chromocell Therapeutics Corp
  1. 4 Planned sale Director sold 797 shares at $21.17 ($16,872)
  2. 4 Planned sale Director sold 558 shares at $20.72 ($11,560)
  3. 4 Planned sale Director sold 786 shares at $21.00 ($16,506)
  4. 4 Planned sale Director sold 558 shares at an average $26.09 ($14,556)
  5. 4 Planned sale Director sold 786 shares at an average $26.16 ($20,561)
  6. 4 Planned sale Director sold 797 shares at an average $26.13 ($20,827)
  7. 4 Planned sale Director sold 283 shares at an average $27.29 ($7,724)
  8. 4 Open-market buy Director bought 35,948 shares at an average $27.82 ($999,983)
  9. 4 Open-market sale CFO, Treas & Secty sold 1,500 shares at $26.84 ($40,265)
  10. 4 Shares withheld for taxes Director gave up 144 shares (to pay taxes)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Planned sale Director sold 590 shares at an average $20.92 ($12,340)
  13. 4 Planned sale Director sold 558 shares at an average $20.92 ($11,671)
  14. 4 Planned sale Director sold 786 shares at an average $20.92 ($16,439)
  15. 4 Planned sale Director sold 797 shares at an average $20.92 ($16,670)
  16. 4/A Grant or award Director acquired 28,012 shares (grant or award)
  17. 4/A Grant or award Director acquired 36,969 shares (grant or award)
  18. 4/A Grant or award Director acquired 28,012 shares (grant or award)
  19. 4/A Grant or award CEO and President acquired 83,678 shares (grant or award)
  20. 4/A Grant or award Director acquired 25,478 shares (grant or award)

Page 1 of 4 · 80 filings